BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37184373)

  • 1. An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy.
    Cowley MV; Pruller J; Ganassi M; Zammit PS; Banerji CRS
    Elife; 2023 May; 12():. PubMed ID: 37184373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
    Tassin A; Laoudj-Chenivesse D; Vanderplanck C; Barro M; Charron S; Ansseau E; Chen YW; Mercier J; Coppée F; Belayew A
    J Cell Mol Med; 2013 Jan; 17(1):76-89. PubMed ID: 23206257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of
    Duranti E; Villa C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
    Banerji CRS; Zammit PS
    Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
    Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
    Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
    Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
    Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
    Jagannathan S
    Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase A activation inhibits
    Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
    J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
    Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
    Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
    Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
    J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells.
    Jagannathan S; Shadle SC; Resnick R; Snider L; Tawil RN; van der Maarel SM; Bradley RK; Tapscott SJ
    Hum Mol Genet; 2016 Oct; 25(20):4419-4431. PubMed ID: 28171552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
    Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
    Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering transcription dysregulation in FSH muscular dystrophy.
    Ehrlich M; Lacey M
    J Hum Genet; 2012 Aug; 57(8):477-84. PubMed ID: 22718021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy.
    Runfola V; Giambruno R; Caronni C; Pannese M; Andolfo A; Gabellini D
    Cell Rep; 2023 Sep; 42(9):113120. PubMed ID: 37703175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FSHD atrophic myotube phenotype is caused by DUX4 expression.
    Vanderplanck C; Ansseau E; Charron S; Stricwant N; Tassin A; Laoudj-Chenivesse D; Wilton SD; Coppée F; Belayew A
    PLoS One; 2011; 6(10):e26820. PubMed ID: 22053214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia enhances human myoblast differentiation: involvement of HIF1α and impact of DUX4, the FSHD causal gene.
    Nguyen TH; Paprzycki L; Legrand A; Declèves AE; Heher P; Limpens M; Belayew A; Banerji CRS; Zammit PS; Tassin A
    Skelet Muscle; 2023 Dec; 13(1):21. PubMed ID: 38104132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
    van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
    Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p38
    Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
    J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
    Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
    Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
    Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
    Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.